{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:47:29Z","timestamp":1792460849471,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009142","name":"Cancer Care Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ygyno.2025.03.008","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T07:34:34Z","timestamp":1742283274000},"page":"134-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies"],"prefix":"10.1016","volume":"195","author":[{"given":"Dani\u00ebl","family":"de Bondt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Naslazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kupets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Stogios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"de Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hontelez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.03.008_bb0005","unstructured":"IARC, GLOBOCAN 2022, IARC, Accessed 27 January 2025 https:\/\/gco.iarc.who.int\/causes\/infections\/home."},{"key":"10.1016\/j.ygyno.2025.03.008_bb0010","first-page":"5","article-title":"Human papillomavirus (HPV) vaccination for the prevention of HPV 16\/18 induced cervical cancer and its precursors","author":"Damm","year":"2009","journal-title":"GMS Health Technol Assess."},{"issue":"Suppl. 5","key":"10.1016\/j.ygyno.2025.03.008_bb0015","doi-asserted-by":"crossref","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human papillomavirus vaccine introduction--the first five years","volume":"30","author":"Markowitz","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2025.03.008_bb0025","unstructured":"Cervical Cancer Action Global progress in HPV vaccination. https:\/\/cervicalcanceraction.org\/hpv-vaccination\/. Accessed Sep 2021."},{"key":"10.1016\/j.ygyno.2025.03.008_bb0030","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm. Rep."},{"issue":"6","key":"10.1016\/j.ygyno.2025.03.008_bb0035","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","volume":"107","author":"Saraiya","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.ygyno.2025.03.008_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052016","article-title":"Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators","volume":"11","author":"Spayne","year":"2021","journal-title":"BMJ Open"},{"issue":"10197","key":"10.1016\/j.ygyno.2025.03.008_bb0045","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ygyno.2025.03.008_bb0050","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1055-9965.EPI-20-1321","article-title":"The differential risk of cervical Cancer in HPV-vaccinated and -unvaccinated women: a mathematical modeling study","volume":"30","author":"Naslazi","year":"2021","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"4","key":"10.1016\/j.ygyno.2025.03.008_bb0055","first-page":"297","article-title":"Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening","volume":"68","author":"Smith","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.ygyno.2025.03.008_bb0060","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical Cancer: US preventive services task Force recommendation statement","volume":"320","author":"Force","year":"2018","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.ygyno.2025.03.008_bb0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.15321","article-title":"Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination","volume":"4","author":"Grimes","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"9","key":"10.1016\/j.ygyno.2025.03.008_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239611","article-title":"Cost-effectiveness of cervical cancer screening with primary HPV testing for unvaccinated women in Sweden","volume":"15","author":"Fogelberg","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145548","article-title":"Cervical Cancer screening in partly HPV vaccinated cohorts - a cost-effectiveness analysis","volume":"11","author":"Naber","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ygyno.2025.03.008_bb0080","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2012.94","article-title":"Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway","volume":"106","author":"Burger","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.03.008_bb0085","series-title":"May Services Task Force","author":"Kulasingam","year":"2011"},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.008_bb0090","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/S2468-2667(17)30007-5","article-title":"Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program Article","volume":"2","author":"Lew","year":"2017","journal-title":"Lancet Public Health"},{"issue":"3","key":"10.1016\/j.ygyno.2025.03.008_bb0095","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ijc.33850","article-title":"Switching clinic-based cervical cancer screening programs to human papillomavirus self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women","volume":"150","author":"Pedersen","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw216","article-title":"Optimal cervical cancer screening in women vaccinated against human papillomavirus","volume":"109","author":"Kim","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0105","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","article-title":"Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models","volume":"1","author":"Brisson","year":"2016","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.ygyno.2025.03.008_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"Bmj"},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0115","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1473-3099(16)30116-5","article-title":"Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study","volume":"17","author":"Chow","year":"2017","journal-title":"Lancet Infect. Dis."},{"issue":"37","key":"10.1016\/j.ygyno.2025.03.008_bb0120","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1016\/j.vaccine.2012.06.057","article-title":"Reduction of HPV infections through vaccination among at-risk urban adolescents","volume":"30","author":"Cummings","year":"2012","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.ygyno.2025.03.008_bb0125","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1016\/j.vaccine.2018.05.019","article-title":"Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs","volume":"36","author":"Dillner","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.008_bb0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/23744235.2015.1094573","article-title":"Follow-up on oral and cervical human papillomavirus prevalence 2013-2015 in youth at a youth clinic in Stockholm Sweden","volume":"48","author":"Gr\u00fcn","year":"2016","journal-title":"Infect Dis (Lond)."},{"issue":"12","key":"10.1016\/j.ygyno.2025.03.008_bb0135","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect. Dis."},{"issue":"10","key":"10.1016\/j.ygyno.2025.03.008_bb0140","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/cid\/ciw533","article-title":"Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community","volume":"63","author":"Kahn","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.ygyno.2025.03.008_bb0145","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/infdis\/jiy075","article-title":"Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination","volume":"217","author":"Machalek","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ygyno.2025.03.008_bb0150","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/infdis\/jiy249","article-title":"The impact of the national HPV vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010-2016","volume":"218","author":"Mesher","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.ygyno.2025.03.008_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201653","article-title":"Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain","volume":"13","author":"Purri\u00f1os-Hermida","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ygyno.2025.03.008_bb0160","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1158\/1055-9965.EPI-14-0687","article-title":"Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study","volume":"23","author":"S\u00f6derlund-Strand","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"9907","key":"10.1016\/j.ygyno.2025.03.008_bb0165","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(13)61947-9","article-title":"Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of sexual attitudes and lifestyles (Natsal)","volume":"382","author":"Sonnenberg","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ygyno.2025.03.008_bb0170","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"8","key":"10.1016\/j.ygyno.2025.03.008_bb0175","first-page":"1105","article-title":"Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012","volume":"26","author":"Baldur-Felskov","year":"2015","journal-title":"Cancer Causes Control"},{"issue":"6","key":"10.1016\/j.ygyno.2025.03.008_bb0180","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jamaoncol.2016.3609","article-title":"Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era","volume":"3","author":"Benard","year":"2017","journal-title":"JAMA Oncol."},{"issue":"9783","key":"10.1016\/j.ygyno.2025.03.008_bb0185","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ygyno.2025.03.008_bb0190","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2105\/AJPH.2016.303472","article-title":"Ecological Association of Human Papillomavirus Vaccination with cervical dysplasia prevalence in the United States, 2007-2014","volume":"106","author":"Flagg","year":"2016","journal-title":"Am. J. Public Health"},{"issue":"6","key":"10.1016\/j.ygyno.2025.03.008_bb0195","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/cid\/cix455","article-title":"Declines in human papillomavirus (HPV)-associated high-grade cervical lesions after introduction of HPV vaccines in Connecticut, United States, 2008-2015","volume":"65","author":"Niccolai","year":"2017","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.ygyno.2025.03.008_bb0200","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"36","key":"10.1016\/j.ygyno.2025.03.008_bb0205","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1016\/j.vaccine.2021.07.009","article-title":"High-risk HPV prevalence among women undergoing cervical cancer screening: findings a decade after HPV vaccine implementation in British Columbia, Canada","volume":"39","author":"Litwin","year":"2021","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.ygyno.2025.03.008_bb0210","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/ijc.33157","article-title":"Prevalence of high-risk human papillomavirus after HPV-vaccination in Denmark","volume":"147","author":"Lynge","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2025.03.008_bb0215","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/ijc.31119","article-title":"Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I)","volume":"142","author":"Lehtinen","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2025.03.008_bb0220","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/ijc.31989","article-title":"Assessment of herd effects among women and heterosexual men after girls-only HPV16\/18 vaccination in the Netherlands: A repeated cross-sectional study","volume":"144","author":"Woestenberg","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2025.03.008_bb0225","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/infdis\/jiy432","article-title":"Substantial decline in prevalence of vaccine-type and nonvaccine-type human papillomavirus (HPV) in vaccinated and unvaccinated girls 5 years after implementing HPV vaccine in Norway","volume":"218","author":"Feiring","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.008_bb0230","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/LGT.0000000000000659","article-title":"Changes in cervical cytology results and human papillomavirus types among persons screened for cervical cancer, 2007 and 2015\u20132017","volume":"26","author":"Lewis","year":"2022","journal-title":"J Low Genit Tract Dis."},{"issue":"7","key":"10.1016\/j.ygyno.2025.03.008_bb0235","doi-asserted-by":"crossref","first-page":"918","DOI":"10.7326\/M21-3798","article-title":"Human papillomavirus vaccine impact and effectiveness through 12 years after vaccine introduction in the United States, 2003 to 2018","volume":"175","author":"Rosenblum","year":"2022","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3201\/eid2201.150791","article-title":"Human papillomavirus vaccination at a time of changing sexual behavior","volume":"22","author":"Baussano","year":"2016","journal-title":"Emerg. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ygyno.2025.03.008_bb0245","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/infdis\/jix299","article-title":"Different challenges in eliminating HPV16 compared to other types: a modeling study","volume":"216","author":"Baussano","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.008_bb0250","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/infdis\/jiv368","article-title":"Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs","volume":"213","author":"Elfstr\u00f6m","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"13","key":"10.1016\/j.ygyno.2025.03.008_bb0255","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.vaccine.2013.01.026","article-title":"The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis","volume":"31","author":"Malag\u00f3n","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0260","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/21645515.2015.1054584","article-title":"Projected impact of Cervarix\u2122 vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom","volume":"12","author":"Van Effelterre","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ygyno.2025.03.008_bb0265","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1756-0500-7-109","article-title":"Testing previous model predictions against new data on human papillomavirus vaccination program outcomes","volume":"7","author":"Smith","year":"2014","journal-title":"BMC Res Notes."},{"issue":"8","key":"10.1016\/j.ygyno.2025.03.008_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072088","article-title":"Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach","volume":"8","author":"V\u00e4nsk\u00e4","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0275","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3111\/13696990903546013","article-title":"The cost effectiveness of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in Hungary","volume":"13","author":"Dasbach","year":"2010","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ygyno.2025.03.008_bb0280","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12879-016-1483-5","article-title":"Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria","volume":"16","author":"Boiron","year":"2016","journal-title":"BMC Infect. Dis."},{"issue":"19","key":"10.1016\/j.ygyno.2025.03.008_bb0285","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.vaccine.2013.03.006","article-title":"Estimating the long-term effects of HPV vaccination in Germany","volume":"31","author":"Horn","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.ygyno.2025.03.008_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202924","article-title":"The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: a mathematical modeling study","volume":"13","author":"Matthijsse","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0295","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv282","article-title":"Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States","volume":"108","author":"Brisson","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.ygyno.2025.03.008_bb0300","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1471-0528.2008.01743.x","article-title":"The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in the UK","volume":"115","author":"Dasbach","year":"2008","journal-title":"Bjog"},{"issue":"3","key":"10.1016\/j.ygyno.2025.03.008_bb0305","first-page":"459","article-title":"The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan","volume":"9","author":"Dasbach","year":"2008","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0310","first-page":"19","article-title":"Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health","volume":"2","author":"Schobert","year":"2012","journal-title":"Econ. Rev."},{"issue":"22","key":"10.1016\/j.ygyno.2025.03.008_bb0315","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/djs395","article-title":"Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis","volume":"104","author":"Van de Velde","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.ygyno.2025.03.008_bb0320","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/1471-0528.15106","article-title":"Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis","volume":"125","author":"Tay","year":"2018","journal-title":"Bjog"},{"issue":"11","key":"10.1016\/j.ygyno.2025.03.008_bb0325","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/OLQ.0000000000000199","article-title":"The estimated impact of human papillomavirus vaccine coverage on the lifetime cervical cancer burden among girls currently aged 12 years and younger in the United States","volume":"41","author":"Chesson","year":"2014","journal-title":"Sex. Transm. Dis."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0330","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12879-020-05632-0","article-title":"Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study","volume":"21","author":"Cody","year":"2021","journal-title":"BMC Infect. Dis."},{"issue":"3","key":"10.1016\/j.ygyno.2025.03.008_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091698","article-title":"The impact of HPV female immunization in Italy: model based predictions","volume":"9","author":"Guzzetta","year":"2014","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.ygyno.2025.03.008_bb0340","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1073\/pnas.1515528113","article-title":"National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States","volume":"113","author":"Durham","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0345","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/S2468-2667(17)30238-4","article-title":"Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study","volume":"3","author":"Johnson","year":"2018","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.ygyno.2025.03.008_bb0350","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12962-015-0029-9","article-title":"Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females","volume":"13","author":"Olsen","year":"2015","journal-title":"Cost Eff Resour Alloc."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0355","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.puhe.2014.11.005","article-title":"Efficacy of vaccination against HPV infection to prevent cervical cancer in France","volume":"129","author":"Ribassin-Majed","year":"2015","journal-title":"Public Health"},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.008_bb0360","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/S2468-2667(16)30019-6","article-title":"Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis","volume":"1","author":"Simms","year":"2016","journal-title":"Lancet Public Health"},{"issue":"5","key":"10.1016\/j.ygyno.2025.03.008_bb0365","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1586\/14737167.8.5.491","article-title":"Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model","volume":"8","author":"Dasbach","year":"2008","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.ygyno.2025.03.008_bb0370","first-page":"18","article-title":"HPV-vaccination for the prevention of cervical cancer in Austria: a model based long-term prognosis of cancer epidemiology","author":"Zechmeister","year":"2010","journal-title":"J. Public Health"},{"issue":"3","key":"10.1016\/j.ygyno.2025.03.008_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032251","article-title":"Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies","volume":"7","author":"Ribassin-Majed","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2025.03.008_bb0380","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12962-017-0073-8","article-title":"Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy","volume":"15","author":"Mennini","year":"2017","journal-title":"Cost Eff Resour Alloc."},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.008_bb0385","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.vaccine.2011.10.067","article-title":"Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada","volume":"30","author":"Tully","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2025.03.008_bb0390","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2334-13-304","article-title":"The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia","volume":"13","author":"Uusk\u00fcla","year":"2013","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.008_bb0395","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3747\/co.26.4795","article-title":"Moving toward the elimination of cervical cancer: modelling the health and economic benefits of increasing uptake of human papillomavirus vaccines","volume":"26","author":"Smith","year":"2019","journal-title":"Curr. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.008_bb0400","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ijc.34231","article-title":"HPV type-specific trends in cervical precancers in the United States, 2008 to 2016","volume":"152","author":"Gargano","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.008_bb0405","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad016","article-title":"Incidence of human papillomavirus-related cancers among males and females aged 15\u201334 years in the United States","volume":"7","author":"Guo","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.ygyno.2025.03.008_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106641","article-title":"The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts","volume":"150","author":"Clark","year":"2021","journal-title":"Prev. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.008_bb0415","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/ijc.33513","article-title":"Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: an ecological analysis on the effects of the school-based human papillomavirus vaccination program","volume":"149","author":"Donken","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2025.03.008_bb0420","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1111\/cas.15060","article-title":"A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan","volume":"112","author":"Yagi","year":"2021","journal-title":"Cancer Sci."},{"issue":"10316","key":"10.1016\/j.ygyno.2025.03.008_bb0425","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2025.03.008_bb0430","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.vaccine.2024.01.046","article-title":"Evidence for an HPV one-dose schedule","volume":"42","author":"Stanley","year":"2024","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.ygyno.2025.03.008_bb0435","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/jnci\/djz227","article-title":"Estimating the natural history of cervical carcinogenesis using simulation models: a CISNET comparative analysis","volume":"112","author":"Burger","year":"2020","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:23:59Z","timestamp":1777641839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":86,"alternative-id":["S0090825825000770"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.008","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}